share_log

S-3: Registration statement for specified transactions by certain issuers

S-3: Registration statement for specified transactions by certain issuers

S-3：特定交易註冊聲明
美股SEC公告 ·  11/26 06:12

Moomoo AI 已提取核心訊息

On November 25, 2024, Conduit Pharmaceuticals filed a Form S-3 registration statement with the SEC to register 75 million shares of common stock for resale by Nirland Limited. These shares may be issued upon the conversion of the August 2024 Senior Secured Promissory Note. Conduit will not receive any proceeds from the sale of these shares.The shares are being registered to allow Nirland Limited, the selling stockholder, to offer and sell them from time to time. The shares may be sold at market prices, prices related to market prices, or privately negotiated prices. Conduit's common stock is traded on Nasdaq under the symbol "CDT."This registration is part of Conduit's strategy to manage its financial obligations and provide liquidity options for its stakeholders. Investors are advised to consider the associated risks detailed in the prospectus.
On November 25, 2024, Conduit Pharmaceuticals filed a Form S-3 registration statement with the SEC to register 75 million shares of common stock for resale by Nirland Limited. These shares may be issued upon the conversion of the August 2024 Senior Secured Promissory Note. Conduit will not receive any proceeds from the sale of these shares.The shares are being registered to allow Nirland Limited, the selling stockholder, to offer and sell them from time to time. The shares may be sold at market prices, prices related to market prices, or privately negotiated prices. Conduit's common stock is traded on Nasdaq under the symbol "CDT."This registration is part of Conduit's strategy to manage its financial obligations and provide liquidity options for its stakeholders. Investors are advised to consider the associated risks detailed in the prospectus.
2024年11月25日，Conduit Pharmicals向美國證券交易委員會提交了S-3表格註冊聲明，要求註冊7500萬股普通股供Nirland Limited轉售。這些股票可以在2024年8月優先擔保本票轉換後發行。Conduit 不會從出售這些股票中獲得任何收益。正在註冊這些股票，以允許出售股東Nirland Limited不時發行和出售。股票可以按市場價格、與市場價格相關的價格或私下議定的價格出售。Conduit的普通股在納斯達克上市，股票代碼爲 「cdT」。此次註冊是Conduit管理其財務義務併爲其利益相關者提供流動性選擇的戰略的一部分。建議投資者考慮招股說明書中詳述的相關風險。
2024年11月25日，Conduit Pharmicals向美國證券交易委員會提交了S-3表格註冊聲明，要求註冊7500萬股普通股供Nirland Limited轉售。這些股票可以在2024年8月優先擔保本票轉換後發行。Conduit 不會從出售這些股票中獲得任何收益。正在註冊這些股票，以允許出售股東Nirland Limited不時發行和出售。股票可以按市場價格、與市場價格相關的價格或私下議定的價格出售。Conduit的普通股在納斯達克上市，股票代碼爲 「cdT」。此次註冊是Conduit管理其財務義務併爲其利益相關者提供流動性選擇的戰略的一部分。建議投資者考慮招股說明書中詳述的相關風險。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Aptose Biosciences
    APTO
    -- 0.2790
    Prelude Therapeutics
    PRLD
    -- 1.300
    Aadi Biosciences
    AADI
    -- 3.390
    Abpro Holdings
    ABP
    -- 2.070
    Xilio Therapeutics
    XLO
    -- 1.280

    解鎖榜首股票